Robert Cook, PhD, is the head of generics R&D and SVP of global technical development at Teva.
How FDA's PK Guidance Shapes Teva's Next Biosimilar Program
Robert Cook, PhD, of Teva explains how analytical characterization and PK data will shape its next biosimilar program.
Inside Teva's Denosumab Biosimilar Strategy: Robert Cook, PhD
Teva's Robert Cook, PhD, explains the clinical data, interchangeability, and supply strategy behind its Degevma and Ponlimsi biosimilars.